Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.49 |
| ▸ | HTR3A | P46098 | 2/20 | 0.49 |
| ▸ | HRH1 | P35367 | 7/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15962956 | 0.85 | HTR3A (0.51) | HTR3AHRH1CYP2D6KCNH2CHRM1 | |
| SCHEMBL15963178 | 0.84 | SMN1; SMN2 (0.60) | HTR3A | |
| SCHEMBL7166739 | 0.84 | — | — | |
| SCHEMBL7166738 | 0.84 | — | — | |
| SCHEMBL15962963 | 0.82 | HRH1 (0.46) | HTR3AHRH1CYP2D6KCNH2CHRM1 | |
| SCHEMBL15963186 | 0.82 | CYP2D6 (0.47) | HRH1CYP2D6 | |
| SCHEMBL15963177 | 0.81 | NPSR1 (0.47) | HTR3AHRH1CYP2D6KCNH2CHRM1 | |
| SCHEMBL5229655 | 0.80 | HRH1 (0.73) | HTR3AHRH1CYP2D6KCNH2CHRM1 | |
| SCHEMBL15963180 | 0.80 | CYP2D6 (0.47) | HRH1CYP2D6KCNH2 | |
| Iodide SCHEMBL7625258 | 0.79 | HTR3A (0.59) | HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025129167-A1 | INHIBITORS OF THE SURFACE EXPRESSION OF THE VOLTAGE-GATED SODIUM ION CHANNEL 1.7 (NAV1.7) AND THEIR THERAPEUTIC USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2025-06-19 | — | — | WO | disclosed |